Cresco Labs Inc. (OTCMKTS:CRLBF) Given Consensus Rating of "Buy" by Brokerages

Key Points

• Cresco Labs Inc. has received an average consensus rating of "Buy" from analysts, with two analysts issuing a strong buy and two giving a hold rating.
• The company's stock performance showed a 12-month low of $0.43 and a high of $2.05, with the current market cap at approximately $335.66 million.
• Cresco Labs reported negative earnings per share of ($0.04) for its last quarter, missing the consensus estimate, despite achieving revenue of $165.76 million.

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF - Get Free Report) have received a consensus rating of "Buy" from the four ratings firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company.

Separately, Canaccord Genuity Group cut Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a report on Tuesday, June 3rd.

Cresco Labs Trading Down 10.4%

Shares of Cresco Labs stock traded down $0.07 on Friday, reaching $0.60. The company had a trading volume of 839,112 shares, compared to its average volume of 744,804. The firm has a market cap of $294.81 million, a price-to-earnings ratio of -2.50 and a beta of 1.40. The company has a debt-to-equity ratio of 1.63, a current ratio of 2.75 and a quick ratio of 1.98. The firm's 50-day moving average price is $0.56 and its two-hundred day moving average price is $0.71. Cresco Labs has a 1 year low of $0.43 and a 1 year high of $2.05.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last announced its earnings results on Friday, May 30th. The company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01). The company had revenue of $165.76 million during the quarter, compared to analysts' expectations of $164.37 million. Cresco Labs had a negative return on equity of 21.77% and a negative net margin of 11.86%. As a group, research analysts predict that Cresco Labs will post -0.2 earnings per share for the current fiscal year.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.